FDA Grants Regular Approval to Rucaparib for Metastatic Castration-resistant Prostate Cancer

On December 17, the FDA approved rucaparib for adults with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer previously treated with an androgen receptor-directed therapy. 

For more information, read the FDA announcement and visit the pharmaand website.

Posted on 12/18/2025